BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27177645)

  • 1. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
    Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
    Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells.
    Pezzani R; Rubin B; Redaelli M; Radu C; Barollo S; Cicala MV; Salvà M; Mian C; Mucignat-Caretta C; Simioni P; Iacobone M; Mantero F
    Endocr J; 2014; 61(1):41-53. PubMed ID: 24153038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
    Wang T; Subramanian C; Blagg BSJ; Cohen MS
    Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.
    Tavanti E; Sero V; Vella S; Fanelli M; Michelacci F; Landuzzi L; Magagnoli G; Versteeg R; Picci P; Hattinger CM; Serra M
    Br J Cancer; 2013 Nov; 109(10):2607-18. PubMed ID: 24129234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma.
    Wan XB; Fan XJ; Chen MY; Xu J; Long ZJ; Hua YJ; Ji H; Liu L; Hong MH; Zeng YX; Liu Q
    Cancer Biol Ther; 2009 Aug; 8(15):1500-6. PubMed ID: 19502819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
    De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase inhibitor VX-680 enhances sensitivity of esophageal squamous cell carcinoma cells to cisplatin chemotherapy.
    Kou J; Wang X; Wei Y; Zhao R; Wang X; He J; Li X; Wang X
    Anticancer Drugs; 2021 Oct; 32(9):969-977. PubMed ID: 34016831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
    Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
    Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
    Demeure MJ; Coan KE; Grant CS; Komorowski RA; Stephan E; Sinari S; Mount D; Bussey KJ
    Surgery; 2013 Dec; 154(6):1405-16; discussion 1416. PubMed ID: 24238056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
    Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
    Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
    Mariniello B; Rosato A; Zuccolotto G; Rubin B; Cicala MV; Finco I; Iacobone M; Frigo AC; Fassina A; Pezzani R; Mantero F
    Endocr Relat Cancer; 2012 Aug; 19(4):527-39. PubMed ID: 22673336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
    Borges KS; Andrade AF; Silveira VS; Marco Antonio DS; Vasconcelos EJR; Antonini SRR; Tone LG; Scrideli CA
    Anticancer Drugs; 2017 Jul; 28(6):634-644. PubMed ID: 28410270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors.
    Pereira SS; Monteiro MP; Costa MM; Ferreira J; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    J Cell Biochem; 2019 Jan; 120(1):894-906. PubMed ID: 30256438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
    Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
    Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.